frontiers | Frontiers in Neuroscience

TYPE Correction
PUBLISHED 29 August 2025
DOI 10.3389/fnins.2025.1667076

OPEN ACCESS

EDITED AND REVIEWED BY
David Lynch,
University of Pennsylvania, United States

*CORRESPONDENCE
Kuanyu Li
✉ likuanyu@nju.deu.cn
Tong Qiao
✉ tongqiao@nju.edu.cn

RECEIVED 16 July 2025
ACCEPTED 07 August 2025
PUBLISHED 29 August 2025

CITATION
Shen J, Xu L, Li Y, Dong W, Cai J, Liu Y, Zhao H, Xu T, Holtz EM, Chang Y, Qiao T and Li K (2025) Correction: Protective effects of Hif2 inhibitor PT-2385 on a neurological disorder induced by deficiency of Irp2. *Front. Neurosci.* 19:1667076. doi: 10.3389/fnins.2025.1667076

Correction: Protective effects of Hif2 inhibitor PT-2385 on a neurological disorder induced by deficiency of Irp2

Jiaqi Shen[1], Li Xu[1], Yuxuan Li[1], Weichen Dong[2], Jing Cai[3], Yutong Liu[1], Hongting Zhao[1], Tianze Xu[3], Esther Meyron Holtz[4], Yanzhong Chang[5], Tong Qiao[3]* and Kuanyu Li[1]*

[1]Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, China, [2]Department of Neurology, The Affiliated Jinling Hospital of Nanjing University Medical School, Nanjing, China, [3]Department of Vascular Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, [4]The Laboratory of Molecular Nutrition, Faculty of Biotechnology and Food Engineering, Technion – Israel Institute of Technology, Haifa, Israel, [5]College of Life Science, Hebei Normal University, Shijiazhuang, China

KEYWORDS

iron regulatory protein 2, hypoxia inducible factor 2α, glycolysis, oxidative phosphorylation, iron sulfur cluster, neurodegeneration

A Correction on

Protective effects of Hif2 inhibitor PT-2385 on a neurological disorder induced by deficiency of Irp2

by Shen, J., Xu, L., Li, Y., Dong, W., Cai, J., Liu, Y., Zhao, H., Xu, T., Holtz, E. M., Chang, Y., Qiao, T., and Li, K. (2021). *Front. Neurosci.* 15:715222. doi: 10.3389/fnins.2021.715222

There was a mistake in Figure 3 as published. One image was wrongly used in Figure 3B (left middle one), which is the same as in Figure 3C (right middle one). The corrected Figure 3 appears below.

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

10.3389/fnins.2025.1667076



FIGURE 3
The histological morphology and mitochondrial ultrastructure in the spinal cord and cerebellum of *Irp2*$^{-/-}$ mice are improved after PT-2385 administration. **(A)** The hematoxylin–eosin (H&E)-stained sections of the cerebellum of WT DMSO, *Irp2*$^{-/-}$ DMSO, and *Irp2*$^{-/-}$ PT-2385 mice. The dotted lines indicate Purkinje cell layers (top), and the arrows point to Purkinje cells (middle). The Purkinje cells framed by the dotted line are magnified four times (bottom). The scale bars are 160, 80, and 20 μm, respectively. **(B, C)** Transmission electron micrographs of the cerebellum **(B)** and spinal cord **(C)** of WT DMSO, *Irp2*$^{-/-}$ DMSO, and *Irp2*$^{-/-}$ PT-2385 mice. The scale bars are 1, 2.5, and 5 μm, respectively. The bottom panels are magnified images of myelin sheath and axonal degeneration. **(D)** The quantification of a normal mitochondria (relative ratio comparing with that in WT). Values represented the mean ± SD, $n = 3$. The ANOVA was used for statistics to evaluate the group differences. $^{*}P < 0.05$, $^{****}P < 0.0001$, *Irp2*$^{-/-}$ DMSO vs. WT DMSO; $^{\#}P < 0.05$, $^{\#\#}P < 0.01$, *Irp2*$^{-/-}$ PT-2385 vs. *Irp2*$^{-/-}$ DMSO.